Daglutril
Alternative Names: KC 12615; SLV-306Latest Information Update: 29 Apr 2015
At a glance
- Originator Solvay Pharmaceuticals
- Developer AbbVie
- Class Antihypertensives; Heart failure therapies; Sulfhydryl compounds
- Mechanism of Action Endothelin-converting enzyme 1 inhibitors; Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 29 Apr 2015 Daglutril is available for licensing in World as of 29 Apr 2015.
- 13 Feb 2013 No development reported - Phase-II for Heart failure in Germany (PO)
- 13 Feb 2013 No development reported - Phase-II for Heart failure in USA (PO)